What Respiree does
Respiree makes wearable cardio-respiratory sensors, including the chest-worn RS001, paired with predictive algorithms on its iRIS Connected Care Platform to continuously track respiratory rate, heart rate, SpO2, temperature and other vital signs from hospital wards to patients' homes. The company says its AI platform supports earlier, more precise clinical decision-making and deterioration detection. Respiree's device has US FDA 510(k) clearance and regulatory clearance in Europe and Australia, and the company lists Roche's navify marketplace and the AVIA Health intelligence platform among its distribution partners. The company is expanding into North America, with plans for a US base in Houston.
Respiree is a healthcare tool on Falcoscan. AI wearable sensors and predictive algorithms for cardio-respiratory monitoring. Falcoscan rates Respiree with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Respiree is founded in 2017, currently at Series_a stage. Pricing: Paid.